Insider · CIK 0001700836
David Moatazedi
Files at BMRA (BIOMERICA INC), EOLS (Evolus, Inc.). First filing Dec 26, 2024, latest Sep 4, 2026.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EOLS: Evolus, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 44Moderate | EOLSsell Evolus, Inc. | $950k 105,108 shares | -17% | - | |
| 11Weak | Evolus, Inc. | $65k 13,669 shares | -2% | +12% from low-65% from high | |
| 12Weak | Evolus, Inc. | $571k 116,720 shares | -16% | +19% from low-64% from high | |
| 11Weak | Evolus, Inc. | $75k 10,539 shares | -3% | +25% from low-52% from high | |
| 50Moderate | EOLSsell Evolus, Inc. | $1.3M 127,905 shares | -26% | +8% from low-43% from high | |
| 21Weak | Evolus, Inc. | $156k 15,787 shares | -3% | +7% from low-43% from high | |
| 19Weak | Evolus, Inc. | $78k 6,251 shares | -1% | - | |
| 40Moderate | Evolus, Inc. | $1.4M 103,376 shares | -17% | - | |
| 20Weak | Evolus, Inc. | $114k 10,502 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | EOLS Evolus, Inc. | SOpen-market sale Common Stock | -105,108 | $9.04 | $950k | 499,592 | 38 d ago |
| Mar 20, 2026 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -13,669 | $4.75 | $65k | 604,700 | Mar 20, 2026 |
| Mar 16, 2026 | EOLS Evolus, Inc. | MOption exercise Common Stock10b5-1 | +67,489 | $0.00 | $0 | 735,089 | Mar 18, 2026 |
| Mar 17, 2026 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -116,720 | $4.89 | $571k | 618,369 | Mar 18, 2026 |
| Mar 16, 2026 | EOLS Evolus, Inc. | MOption exercise Performance Restricted Stock Unitsderivative10b5-1 | -67,489 | $0.00 | $0 | 67,488 | Mar 18, 2026 |
| Feb 17, 2026 | EOLS Evolus, Inc. | AGrant or award Common Stock | +313,212 | $0.00 | $0 | 667,600 | Feb 19, 2026 |
| Feb 17, 2026 | EOLS Evolus, Inc. | AGrant or award Performance Restricted Stock Unitsderivative | +626,424 | $0.00 | $0 | 626,424 | Feb 19, 2026 |
| Feb 17, 2026 | EOLS Evolus, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +457,541 | $0.00 | $0 | 457,541 | Feb 19, 2026 |
| Dec 12, 2025 | BMRA BIOMERICA INC | AGrant or award Common stock | +20,000 | $0.00 | $0 | 30,625 | Dec 31, 2025 |
| Dec 22, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -10,539 | $7.15 | $75k | 354,388 | Dec 29, 2025 |
| Jun 13, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock | -111,323 | $10.05 | $1.1M | 381,509 | Jun 16, 2025 |
| Jun 16, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock | -16,582 | $9.89 | $164k | 364,927 | Jun 16, 2025 |
| May 12, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -15,787 | $9.87 | $156k | 492,832 | May 14, 2025 |
| Mar 27, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -6,251 | $12.40 | $78k | 508,619 | Mar 28, 2025 |
| Mar 18, 2025 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -103,376 | $13.26 | $1.4M | 514,870 | Mar 20, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Common Stock | +95,399 | $0.00 | $0 | 618,246 | Mar 11, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Performance Restricted Stock Unitsderivative | +190,799 | $0.00 | $0 | 190,799 | Mar 11, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +135,925 | $0.00 | $0 | 135,925 | Mar 11, 2025 |
| Dec 23, 2024 | EOLS Evolus, Inc. | SOpen-market sale Common Stock10b5-1 | -10,502 | $10.85 | $114k | 522,847 | Dec 26, 2024 |
| Dec 13, 2024 | BMRA BIOMERICA INC | AGrant or award Common stock | +85,000 | $0.31 | $26k | 85,000 | Dec 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.